The Valley Desk

NCT05456685 · Interventional trial

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Overall registry status Active not recruiting

Phase 2

Conditions Fallopian Tube Cancer, High Grade Ovarian Cancer, Primary Peritoneal Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov